The startup develops specialized catheters designed to reduce high failure rates associated with peripheral intravenous catheters (PIVCs). Their technology includes advanced drug delivery systems and catheter designs that facilitate effective liquid administration to nasal cavities and sinuses in medical, dental, and veterinary applications.
Funding
Funding not disclosed
Founders
Product
Problem
Peripheral intravenous catheters (PIVCs) frequently fail, leading to repeated needlesticks, increased healthcare costs, and potential complications such as phlebitis and blockages. Current PIVC designs often contribute to mechanical forces on the vein wall, causing inflammation and early device failure.
Solution
Flomatrix is developing a novel PIVC tip technology, FloRamp, designed to reduce the high failure rates associated with standard PIVCs. The patented FloRamp design redirects fluid flow away from the vein wall and into the center of the venous blood flow, reducing mechanical forces by at least 60% compared to existing IV catheters. By minimizing these forces, FloRamp aims to decrease inflammation, blockages, and overall PIVC failure rates, ultimately improving patient outcomes and reducing healthcare costs. The FloRamp technology can be integrated into existing IV catheter manufacturing processes, potentially allowing for rapid market entry.
Target Audience
Flomatrix's primary target audience includes hospitals, clinics, and other healthcare providers seeking to reduce PIVC failure rates and improve patient satisfaction, as well as existing IV catheter manufacturers looking to enhance their product offerings with innovative technology.
Features
- Ramped catheter tip design to direct fluid flow away from the vein wall
- Reduction of mechanical forces acting on the vein by at least 60% compared to standard PIVCs
- Demonstrated reduction in catheter blockages compared to a market-leading device
- Lower Visual Infusion Phlebitis (VIP) scores, indicating reduced inflammation
- Less internal damage to the vein, supported by histopathological findings
- Straightforward regulatory pathway, potentially not requiring a new 510(k) application for integration by existing manufacturers